High-Flow Nasal Cannula Oxygen Therapy versus Non-Invasive Ventilation for AECOPD Patients After Extubation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Zhouzhou Feng,Lu Zhang,Haichuan Yu,Xiaojie Su,Tiankui Shuai,Lei Zhu,De Chen,Jian Liu
DOI: https://doi.org/10.2147/COPD.S375107
2022-08-31
International Journal of COPD
Abstract:Zhouzhou Feng, Lu Zhang, Haichuan Yu, Xiaojie Su, Tiankui Shuai, Lei Zhu, De Chen, Jian Liu The First Clinical Medical College, Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China Correspondence: Jian Liu, The first clinical medical college, Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China, Email Objective: To evaluate the clinical efficacy of high-flow nasal oxygen therapy (HFNC) and non-invasive ventilation (NIV) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) after extubation. Research Methods: This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statements. The primary outcome measures analyzed included: reintubation rate, mortality, complication rate, and ICU length of stay. Results: Eight studies were included, with a total of 612 subjects, including 297 in the HFNC group and 315 in the NIV group. The effect of HFNC and NIV on the reintubation rate of AECOPD patients after extubation, RR (1.49 [95% CI,0.95 to 2.33], P = 0.082). Subgroup analysis with or without hypercapnia according to the included AECOPD population, with hypercapnia, RR (0.69 [95% CI,0.33 to 1.44], P=0.317), without hypercapnia, RR (2.61 [95% CI,1.41 to 4.83], P=0.002). Mortality, RR (0.92 [95% CI,0.56 to 1.52], P = 0.752). ICU length of stay, MD (− 0.44 [95% CI,-1.01 to 0.13], P = 0.132). Complication rate, RR (0.22 [95% CI,0.13 to 0.39], P = 0.000). After subgroup analysis, the reintubation rate of HFNC and NIV has no statistical difference in patients with hypercapnia, but NIV can significantly reduce the reintubation rate in patients without hypercapnia. In the outcome measures of complication rate, HFNC significantly reduced complication rate compared with NIV. In mortality and ICU length of stay, analysis results showed that HFNC and NIV were not statistically different. Conclusion: According to the available evidence, the application of HFNC can be used as an alternative treatment for NIV after extubation in AECOPD patients with hypercapnia, but in the patients without hypercapnia, HFNC is less effective than NIV. Keywords: nasal high-flow oxygen therapy, acute exacerbation of chronic obstructive pulmonary disease, non-invasive ventilation, meta-analysis Chronic obstructive pulmonary disease (COPD) is a common chronic disease characterized by persistent airflow limitation. 1 Over the past few decades, the morbidity and mortality of COPD has increased exponentially, affecting the global About 384 million people, it is now considered the third leading cause of death globally. 2 Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is defined as an acute worsening of respiratory symptoms that require additional treatment, with significant negative impact on health status, hospitalization, readmission, disease progression, and mortality. It not only seriously affects the quality of life of patients, but also imposes a heavy economic burden on families, medical systems and society. 3,4 Non-invasive ventilation (NIV) is the preferred initial mode of ventilator assistance for patients with acute hypercapnic breathing failure caused by AECOPD. 5,6 Compared with invasive mechanical ventilation (IMV), AECOPD patients treated with NIV has lower in-hospital mortality, shorter hospital stay and lower cost. 7,8 With the development of medicine, invasive-noninvasive sequential ventilation strategy has become an effective way to wean off invasive mechanical ventilation in patients with AECOPD. And it has significantly reduced weaning-related mortality, pneumonia and ventilation time. 9 High Flow Nasal Cannula (HFNC) is a new type of non-invasive breathing assistance method that can improve ventilation and oxygen by providing precise oxygen concentration heated and humidified oxygen, better tolerance and comfort than NIV. 10 It may reduce the volume of dead space and increase the alveolar volume, which can result in improvement of alveolar ventilation and gas exchange. 11 For COPD patients with type II respiratory failure and pH between 7.25 and 7.35, HFNC was statistically non-inferior to NIV as initial ventilatory support in decreasing PaCO2 after 2h of treatment in patients with mild-to-moderate AECOPD. 12 A recent meta-analysis study showed that HFNC is more beneficial than NIV in the treatment of COPD and hypercapnic respiratory failure. 13 However, in the process of weaning of AECOPD patients, the therapeutic effect of HFNC and whether it can be used as an alternative therapy for NIV is still unclear. Therefore, in this study, the method of meta-analysis was u -Abstract Truncated-